David Lu

1.7k total citations · 1 hit paper
27 papers, 1.2k citations indexed

About

David Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, David Lu has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in David Lu's work include Prostate Cancer Treatment and Research (10 papers), Cancer Cells and Metastasis (9 papers) and Cancer Genomics and Diagnostics (8 papers). David Lu is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Cancer Cells and Metastasis (9 papers) and Cancer Genomics and Diagnostics (8 papers). David Lu collaborates with scholars based in United States, United Kingdom and Canada. David Lu's co-authors include Ryan Dittamore, Ryon P. Graf, Nicole A. Schreiber, Howard I. Scher, Martin Fleisher, Brigit McLaughlin, Glenn Heller, Jessica Louw, Adam Jendrisak and Ann Johnson and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David Lu

27 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

2016 461 citations Howard I. Scher, David Lu et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Lu United States	12	800	594	549	361	118	27	1.2k
Stephanie Greene United States	9	563 0.7×	507 0.9×	443 0.8×	458 1.3×	83 0.7×	18	1.3k
Alison Reid United Kingdom	13	746 0.9×	400 0.7×	306 0.6×	412 1.1×	98 0.8×	20	1.1k
Carl Le United States	7	740 0.9×	372 0.6×	249 0.5×	584 1.6×	89 0.8×	10	1.2k
Yongde Liao China	18	425 0.5×	281 0.5×	317 0.6×	453 1.3×	99 0.8×	75	1.1k
Holger H.H. Erb Germany	17	453 0.6×	393 0.7×	366 0.7×	626 1.7×	77 0.7×	58	1.2k
Andreas Josefsson Sweden	18	456 0.6×	222 0.4×	257 0.5×	340 0.9×	43 0.4×	38	935
Roberta Caputo Italy	13	664 0.8×	317 0.5×	805 1.5×	612 1.7×	27 0.2×	27	1.4k
Maria Thadani‐Mulero United States	7	521 0.7×	255 0.4×	203 0.4×	307 0.9×	84 0.7×	11	797
Yuanjie Niu China	20	582 0.7×	413 0.7×	279 0.5×	703 1.9×	86 0.7×	49	1.2k
Suman Bhattacharya United States	12	538 0.7×	370 0.6×	713 1.3×	346 1.0×	110 0.9×	26	1.2k

Countries citing papers authored by David Lu

Since Specialization

Citations

This map shows the geographic impact of David Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lu more than expected).

Fields of papers citing papers by David Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lu. The network helps show where David Lu may publish in the future.

Co-authorship network of co-authors of David Lu

This figure shows the co-authorship network connecting the top 25 collaborators of David Lu. A scholar is included among the top collaborators of David Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Lu. David Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lu, David, Michael J. Grant, Steven E. Stayrook, et al.. (2022). Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. Nature Communications. 13(1). 6791–6791. 17 indexed citations

Lu, David, Rachel Krupa, Melissa Harvey, et al.. (2020). Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer. SHILAP Revista de lepidopterología. 9(1). 13–19. 8 indexed citations

Truini, Anna, Jacqueline H. Starrett, Tyler F. Stewart, et al.. (2019). The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research. 25(21). 6382–6391. 38 indexed citations

Byers, Lauren A., et al.. (2019). Abstract 2215: SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer. Cancer Research. 79(13_Supplement). 2215–2215. 4 indexed citations

Scher, Howard I., Ryon P. Graf, Nicole A. Schreiber, et al.. (2018). Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncology. 4(9). 1179–1179. 160 indexed citations

Boffa, Daniel J., Ryon P. Graf, Michelle C. Salazar, et al.. (2017). Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. Cancer Epidemiology Biomarkers & Prevention. 26(7). 1139–1145. 61 indexed citations

Scher, Howard I., Ryon P. Graf, Nicole A. Schreiber, et al.. (2017). Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. Cancer Research. 77(20). 5687–5698. 94 indexed citations

Krupa, Rachel, David Lu, Ryon P. Graf, et al.. (2016). Characterization of programmed cell death-1 ligand (PD-L1) expression in circulating tumor cells (CTCs) of lung cancer. Journal of Thoracic Oncology. 11(2). S52–S52. 1 indexed citations

Graf, Ryon P., David Lu, Rachel Krupa, et al.. (2016). PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study. Annals of Oncology. 27. vi22–vi22. 1 indexed citations

10.

Anantharaman, Archana, Terence W. Friedlander, David Lu, et al.. (2016). Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer. 16(1). 744–744. 90 indexed citations

11.

Anantharaman, Archana, Terence W. Friedlander, David Lu, et al.. (2016). Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle invasive and metastatic bladder cancer patients.. Journal of Clinical Oncology. 34(2_suppl). 446–446. 3 indexed citations

12.

Scher, Howard I., Ryon P. Graf, Nicole A. Schreiber, et al.. (2016). Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. European Urology. 71(6). 874–882. 129 indexed citations

13.

Scher, Howard I., Ryon P. Graf, Nicole A. Schreiber, et al.. (2016). AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy.. Journal of Clinical Oncology. 34(15_suppl). 5013–5013. 4 indexed citations

14.

Boffa, Daniel J., Jorge J. Nieva, Lyudmila Bazhenova, et al.. (2016). Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort.. Journal of Clinical Oncology. 34(15_suppl). 8524–8524. 1 indexed citations

15.

Lu, David, Ryon P. Graf, Melissa Harvey, et al.. (2015). Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells. PubMed. 4. 4–4. 8 indexed citations

16.

Lu, David, et al.. (2015). Development of a New Approach for the Therapy of Prostate Cancer with SPOP Mutations. Journal of Cancer Therapy. 6(10). 841–848. 2 indexed citations

17.

Scher, Howard I., Jessica Louw, Adam Jendrisak, et al.. (2015). Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 33(7_suppl). 147–147. 3 indexed citations

18.

Wang, Yujun, Ernest Han, Jin Yan, et al.. (2014). Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells. Cancer Letters. 358(2). 170–179. 75 indexed citations

19.

Gao, Jinbo, Yujun Wang, Jin Yan, et al.. (2011). Identification of a Natural Compound by Cell-Based Screening That Enhances Interferon Regulatory Factor-1 Activity and Causes Tumor Suppression. Molecular Cancer Therapeutics. 10(10). 1774–1783. 15 indexed citations

20.

Lu, David, et al.. (2004). T-Cell and NK/T-Cell Lymphomas in Southern Taiwan: A Study of 72 Cases in a Single Institute. Leukemia & lymphoma. 45(5). 923–928. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact